TY - JOUR T1 - The prevention of virus-induced exacerbation of bronchial asthma in children JF - European Respiratory Journal JO - Eur Respir J VL - 40 IS - Suppl 56 SP - 3283 AU - Elena Kondiurina AU - Tatiana Elkina AU - Maria Shteinberg AU - Natalia Goulevskaia AU - Yulia Tatarenko Y1 - 2012/09/01 UR - http://erj.ersjournals.com/content/40/Suppl_56/3283.abstract N2 - Background: The viral infection is the most common trigger of bronchial asthma. The role of antiviral therapy in prevention of virus-induced bronchial asthma exacerbations in chil-dren is still unknown.Aim: To evaluate the efficacy and safety of ultralow doses of antibodies to interferon-γ (ULD AB IFN-γ) - IFN-inducer («Anaferon») in treatment of patients with virus-induced phenotypes of bronchial asthma.Methods: A comparative, randomized, double-blind placebo-controlled trial of ULD AB IFN-γ (anaferon for children) efficacy in prevention of acute respiratory viral infections (ARVI) and bronchial asthma exacerbations in a 100 children of 1-5 years with virus-induced phenotype of mild and moderate bronchial asthma. 52 patients of the treatment group obtained ULD AB IFN-γ (anaferon) for children in preventive regimen (1 pill 1 time per day for 3 months) and 48 patients of the comparison group took placebo in the same way.Results: During 3-months follow-up period the mean number of acute respiratory viral infections in treatment group was 0,6±0,14 and duration was 4,4±0,4 days; in comparison group children suffered from 1,32±0,18 ARVI episodes with mean duration 8,9±0,9 days. The percent of children with exacerbation of bronchial asthma induced by ARVI was 11,5% and 27% of chil-dren in treatment and comparison groups respectively. Side effects were not registered during the trial.Conclusions: The preventive administration of ULD AB IFN-γ (anaferon) affords to decrease the number of virus-induced bronchial asthma exacerbations, episodes and duration of acute respiratory viral infection. This fact considerably improve the quality of patients' life and decrease economic costs for exacerbation treatment. ER -